nach oben

Current Cardiology Reports

Erschienen in:

17.10.2023 | Hypertension (DS Geller and DL Cohen, Section Editors)

Congenital Cyanotic Heart Disease and the Association with Pheochromocytomas and Paragangliomas

verfasst von: Robert Benson Jones Jr., Debbie L. Cohen

Erschienen in: Current Cardiology Reports | Ausgabe 11/2023

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Pheochromocytomas and paragangliomas (PPGLs) are rare neuroendocrine tumors that commonly produce excess catecholamines causing significant morbidity and mortality. Patients with cyanotic congenital heart disease (CCHD) develop PPGLs at a higher frequency than the general population. This review will summarize recent research in the association of PPGL and CCHD.

Recent Findings

Advances in molecular genetics have provided new insights into a variety of germline mutations and somatic mutations related to PPGLs. In the CCHD population, mutations can occur in the hypoxia signaling pathway with gain-of-function somatic mutations in EPAS1, which prevent degradation of hypoxia-inducible factor-2 alpha. These mutations are implicated in oncogenesis. PPGLs associated with CCHD develop as early as age 15 years and have predominantly noradrenergic secretion. Surgical removal is considered the first line of therapy, although belzutifan, a HIF-2α inhibitor, is currently being tested as a potential therapy.

Summary

Early screening with plasma metanephrines may assist in identifying PPGLs in patients with CCHD.

•• Pacak K. New biology of pheochromocytoma and paraganglioma. Endocr Pract. 2022;28(12):1253-69. https://doi.org/10.1016/j.eprac.2022.09.003. A thorough review of the most recent advancements in PPGL biochemical, genetic, and therapeutic advancements.

Dahia PLM. Pheochromocytoma and paraganglioma pathogenesis: learning from genetic heterogeneity. Nat Rev Cancer. 2014;14(2):108–19. https://doi.org/10.1038/nrc3648.CrossRefPubMed

Erickson D, Kudva YC, Ebersold MJ, Thompson GB, Grant CS, van Heerden JA, et al. Benign paragangliomas: clinical presentation and treatment outcomes in 236 patients. J Clin Endocrinol Metab. 2001;86(11):5210–6. https://doi.org/10.1210/jcem.86.11.8034.CrossRefPubMed

Fishbein L, Leshchiner I, Walter V, Danilova L, Robertson AG, Johnson AR, et al. Comprehensive molecular characterization of pheochromocytoma and paraganglioma. Cancer Cell. 2017;31(2):181–93. https://doi.org/10.1016/j.ccell.2017.01.001.CrossRefPubMedPubMedCentral

Dahia PLM, Toledo RA. Recognizing hypoxia in phaeochromocytomas and paragangliomas. Nat Rev Endocr. 2020;16(4):191–2. https://doi.org/10.1038/s41574-020-0324-1.CrossRef

McQuillen PS, Goff DA, Licht DJ. Effects of congenital heart disease on brain development. Prog Pediatr Cardiol. 2010;29(2):79–85. https://doi.org/10.1016/j.ppedcard.2010.06.011.CrossRefPubMedPubMedCentral

Moons P, Bovijn L, Budts W, Belmans A, Gewillig M. Temporal trends in survival to adulthood among patients born with congenital heart disease from 1970 to 1992 in Belgium. Circulation. 2010;122(22):2264–72. https://doi.org/10.1161/circulationaha.110.946343.CrossRefPubMed

Marelli AJ, Ionescu-Ittu R, Mackie AS, Guo L, Dendukuri N, Kaouache M. Lifetime prevalence of congenital heart disease in the general population from 2000 to 2010. Circulation. 2014;130(9):749–56. https://doi.org/10.1161/circulationaha.113.008396.CrossRefPubMed

• Ogasawara T, Fujii Y, Kakiuchi N, Shiozawa Y, Sakamoto R, Ogawa Y, Ootani K, Ito E, Tanaka T, Watanabe K, Yoshida Y. Genetic analysis of pheochromocytoma and paraganglioma complicating cyanotic congenital heart disease. J Clin Endocrinol Metab. 2022;107(9):2545-55. https://doi.org/10.1210/clinem/dgac362. This study of CCHD-PPGL patients found 15/16 samples carried somaticmutation for EPAS1, suggesting that selective pressure of hypoxia can lead to this mutation.

10.

•• Opotowsky AR, Moko LE, Ginns J, Rosenbaum M, Greutmann M, Aboulhosn J, et al. Pheochromocytoma and paraganglioma in cyanotic congenital heart disease. J Clin Endocrinol Metab. 2015;100(4):1325-34. https://doi.org/10.1210/jc.2014-3863. This study performed clinical, biochemical, and genetic analysis of a cohort of 18 CCHD-PPGL patients and identified noradrenergic, rather than adrenergic, biochemical predominance.

11.

Ponz de Antonio I, Ruiz Cantador J, González García AE, Oliver Ruiz JM, Sánchez-Recalde Á, López-Sendón JL. Prevalence of neuroendocrine tumors in patients with cyanotic congenital heart disease. Rev Esp Cardiol (Engl Ed). 2017;70(8):673-5. https://doi.org/10.1016/j.rec.2016.09.036.

12.

• Dahia PLM, Clifton-Bligh R, Gimenez-Roqueplo A-P, Robledo M, Jimenez C. Hereditary endocrine tumours: current state-of-the-art and research opportunities: metastatic pheochromocytomas and paragangliomas: proceedings of the MEN2019 workshop. Endocrine-Related Cancer. 2020;27(8):T41-T52. https://doi.org/10.1530/erc-19-0435. An excellent review of the current genetic and potential therapeutic targets for PPGL.

13.

Kaelin WG Jr, Ratcliffe PJ, Semenza GL. Pathways for oxygen regulation and homeostasis: the 2016 Albert Lasker basic medical research award. Jama. 2016;316(12):1252–3. https://doi.org/10.1001/jama.2016.12386.CrossRefPubMed

14.

Nilsson H, Jögi A, Beckman S, Harris AL, Poellinger L, Påhlman S. HIF-2α expression in human fetal paraganglia and neuroblastoma: relation to sympathetic differentiation, glucose deficiency, and hypoxia. Exp Cell Res. 2005;303(2):447–56. https://doi.org/10.1016/j.yexcr.2004.10.003.CrossRefPubMed

15.

Kim LC, Simon MC. Hypoxia-inducible factors in cancer. Cancer Res. 2022;82(2):195–6. https://doi.org/10.1158/0008-5472.Can-21-3780.CrossRefPubMedPubMedCentral

16.

Ivan M, Kondo K, Yang H, Kim W, Valiando J, Ohh M, et al. HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science. 2001;292(5516):464–8. https://doi.org/10.1126/science.1059817.CrossRefPubMed

17.

Latif F, Tory K, Gnarra J, Yao M, Duh FM, Orcutt ML, et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science. 1993;260(5112):1317–20. https://doi.org/10.1126/science.8493574.CrossRefPubMed

18.

Burnichon N, Vescovo L, Amar L, Libé R, de Reynies A, Venisse A, et al. Integrative genomic analysis reveals somatic mutations in pheochromocytoma and paraganglioma. Hum Mol Genet. 2011;20(20):3974–85. https://doi.org/10.1093/hmg/ddr324.CrossRefPubMed

19.

López-Jiménez E, Gómez-López G, Leandro-García LJ, Muñoz I, Schiavi F, Montero-Conde C, et al. Research resource: transcriptional profiling reveals different pseudohypoxic signatures in SDHB and VHL-related pheochromocytomas. Mol Endocrinol. 2010;24(12):2382–91. https://doi.org/10.1210/me.2010-0256.CrossRefPubMedPubMedCentral

20.

Eisenhofer G, Huynh TT, Pacak K, Brouwers FM, Walther MM, Linehan WM, et al. Distinct gene expression profiles in norepinephrine- and epinephrine-producing hereditary and sporadic pheochromocytomas: activation of hypoxia-driven angiogenic pathways in von Hippel-Lindau syndrome. Endocr Relat Cancer. 2004;11(4):897–911. https://doi.org/10.1677/erc.1.00838.CrossRefPubMed

21.

Dahia PL, Ross KN, Wright ME, Hayashida CY, Santagata S, Barontini M, et al. A HIF1alpha regulatory loop links hypoxia and mitochondrial signals in pheochromocytomas. PLoS Genet. 2005;1(1):72–80. https://doi.org/10.1371/journal.pgen.0010008.CrossRefPubMed

22.

Yang C, Zhuang Z, Fliedner SM, Shankavaram U, Sun MG, Bullova P, et al. Germ-line PHD1 and PHD2 mutations detected in patients with pheochromocytoma/paraganglioma-polycythemia. J Mol Med (Berl). 2015;93(1):93–104. https://doi.org/10.1007/s00109-014-1205-7.CrossRefPubMed

23.

Eckardt L, Prange-Barczynska M, Hodson EJ, Fielding JW, Cheng X, Lima J, et al. Developmental role of PHD2 in the pathogenesis of pseudohypoxic pheochromocytoma. Endocr Relat Cancer. 2021;28(12):757–72. https://doi.org/10.1530/erc-21-0211.CrossRefPubMedPubMedCentral

24.

Castro-Vega LJ, Lepoutre-Lussey C, Gimenez-Roqueplo AP, Favier J. Rethinking pheochromocytomas and paragangliomas from a genomic perspective. Oncogene. 2016;35(9):1080–9. https://doi.org/10.1038/onc.2015.172.CrossRefPubMed

25.

Selak MA, Armour SM, MacKenzie ED, Boulahbel H, Watson DG, Mansfield KD, et al. Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. Cancer Cell. 2005;7(1):77–85. https://doi.org/10.1016/j.ccr.2004.11.022.CrossRefPubMed

26.

Smith EH, Janknecht R, Maher LJ 3rd. Succinate inhibition of alpha-ketoglutarate-dependent enzymes in a yeast model of paraganglioma. Hum Mol Genet. 2007;16(24):3136–48. https://doi.org/10.1093/hmg/ddm275.CrossRefPubMed

27.

Losman JA, Koivunen P, Kaelin WG Jr. 2-Oxoglutarate-dependent dioxygenases in cancer. Nat Rev Cancer. 2020;20(12):710–26. https://doi.org/10.1038/s41568-020-00303-3.CrossRefPubMed

28.

Lamy C, Tissot H, Faron M, Baudin E, Lamartina L, Pradon C, et al. Succinate: a serum biomarker of SDHB-mutated paragangliomas and pheochromocytomas. J Clin Endocrinol Metab. 2022;107(10):2801–10. https://doi.org/10.1210/clinem/dgac474.CrossRefPubMed

29.

Zhuang Z, Yang C, Lorenzo F, Merino M, Fojo T, Kebebew E, et al. Somatic HIF2A gain-of-function mutations in paraganglioma with polycythemia. N Engl J Med. 2012;367(10):922–30. https://doi.org/10.1056/NEJMoa1205119.CrossRefPubMedPubMedCentral

30.

Toledo R, Qin Y, Srikantan S, Morales N, Li Q, Deng Y, et al. In vivo and in vitro oncogenic effects of HIF2A mutations in pheochromocytomas and paragangliomas. Endocr Relat Cancer. 2013;20:349–59.CrossRefPubMedPubMedCentral

31.

Comino-Méndez I, de Cubas AA, Bernal C, Álvarez-Escolá C, Sánchez-Malo C, Ramírez-Tortosa CL, et al. Tumoral EPAS1 (HIF2A) mutations explain sporadic pheochromocytoma and paraganglioma in the absence of erythrocytosis. Hum Mol Genet. 2013;22(11):2169–76. https://doi.org/10.1093/hmg/ddt069.CrossRefPubMed

32.

Welander J, Andreasson A, Brauckhoff M, Bäckdahl M, Larsson C, Gimm O, et al. Frequent EPAS1/HIF2α exons 9 and 12 mutations in non-familial pheochromocytoma. Endocr Relat Cancer. 2014;21(3):495–504. https://doi.org/10.1530/erc-13-0384.CrossRefPubMed

33.

Arias-Stella J, Valcarcel J. Chief cell hyperplasia in the human carotid body at high altitudes; physiologic and pathologic significance. Hum Pathol. 1976;7(4):361–73. https://doi.org/10.1016/s0046-8177(76)80052-4.CrossRefPubMed

34.

Rodriguez-Cuevas H, Lau I, Rodriguez HP. High-altitude paragangliomas diagnostic and therapeutic considerations. Cancer. 1986;57(3):672–6. https://doi.org/10.1002/1097-0142(19860201)57:3%3c672::aid-cncr2820570346%3e3.0.co;2-c.CrossRefPubMed

35.

Gonzalez-Urquijo M, Hinojosa-Gonzalez DE, Fabiani MA, González-González M, Cardenas-Figueroa EG, Rosero-Aguirre VA, et al. High altitude carotid body tumors growth during active surveillance. Vasc Endovascular Surg. 2023;57(5):451–5. https://doi.org/10.1177/15385744231154089.CrossRefPubMed

36.

Saldana MJ, Salem LE, Travezan R. High altitude hypoxia and chemodectomas. Human Pathol. 1973;4(2):251–63. https://doi.org/10.1016/S0046-8177(73)80012-7.CrossRef

37.

Vaidya A, Flores SK, Cheng Z-M, Nicolas M, Deng Y, Opotowsky AR, et al. EPAS1 mutations and paragangliomas in cyanotic congenital heart disease. N Engl J Med. 2018;378(13):1259–61. https://doi.org/10.1056/NEJMc1716652.CrossRefPubMedPubMedCentral

38.

• Zhao B, Zhou Y, Zhao Y, Zhao Y, Wu X, Bi Y, et al. Co-occurrence of pheochromocytoma-paraganglioma and cyanotic congenital heart disease: a case report and literature review. Front Endocrinol (Lausanne). 2018;9:165. https://doi.org/10.3389/fendo.2018.00165. A collection of 47 case reports of CCHD-PPGL, this study provides the largest published collection of CCHD-PPGL.

39.

Eisenhofer G, Lenders JW, Timmers H, Mannelli M, Grebe SK, Hofbauer LC, et al. Measurements of plasma methoxytyramine, normetanephrine, and metanephrine as discriminators of different hereditary forms of pheochromocytoma. Clin Chem. 2011;57(3):411–20. https://doi.org/10.1373/clinchem.2010.153320.CrossRefPubMedPubMedCentral

40.

Eisenhofer G, Walther MM, Huynh TT, Li ST, Bornstein SR, Vortmeyer A, et al. Pheochromocytomas in von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2 display distinct biochemical and clinical phenotypes. J Clin Endocrinol Metab. 2001;86(5):1999–2008. https://doi.org/10.1210/jcem.86.5.7496.CrossRefPubMed

41.

Pacak K, Jochmanova I, Prodanov T, Yang C, Merino MJ, Fojo T, et al. New syndrome of paraganglioma and somatostatinoma associated with polycythemia. J Clin Oncol. 2013;31(13):1690–8. https://doi.org/10.1200/jco.2012.47.1912.CrossRefPubMedPubMedCentral

42.

Jasim S, Jimenez C. Metastatic pheochromocytoma and paraganglioma: management of endocrine manifestations, surgery and ablative procedures, and systemic therapies. Best Pract Res Clin Endocrinol Metab. 2020;34(2): 101354. https://doi.org/10.1016/j.beem.2019.101354.CrossRefPubMed

43.

Ayala-Ramirez M, Feng L, Habra MA, Rich T, Dickson PV, Perrier N, et al. Clinical benefits of systemic chemotherapy for patients with metastatic pheochromocytomas or sympathetic extra-adrenal paragangliomas. Cancer. 2012;118(11):2804–12. https://doi.org/10.1002/cncr.26577.CrossRefPubMed

44.

Roodhart MJ, Langenberg HM, Witteveen E, Voest EE. The molecular basis of class side effects due to treatment with inhibitors of the VEGF/VEGFR pathway. Curr Clin Pharmacol. 2008;3(2):132–43. https://doi.org/10.2174/157488408784293705.CrossRefPubMed

45.

Kohlenberg J, Welch B, Hamidi O, Callstrom M, Morris J, Sprung J, et al. Efficacy and safety of ablative therapy in the treatment of patients with metastatic pheochromocytoma and paraganglioma. Cancers. 2019;11(2):195.CrossRefPubMedPubMedCentral

46.

Gravel G, Leboulleux S, Tselikas L, Fassio F, Berraf M, Berdelou A, et al. Prevention of serious skeletal-related events by interventional radiology techniques in patients with malignant paraganglioma and pheochromocytoma. Endocrine. 2018;59(3):547–54. https://doi.org/10.1007/s12020-017-1515-y.CrossRefPubMed

47.

Pryma DA, Chin BB, Noto RB, Dillon JS, Perkins S, Solnes L, et al. Efficacy and safety of high-specific-activity ¹³¹I-MIBG therapy in patients with advanced pheochromocytoma or paraganglioma. J Nucl Med. 2019;60(5):623–30. https://doi.org/10.2967/jnumed.118.217463.CrossRefPubMedPubMedCentral

48.

Fallah J, Brave MH, Weinstock C, Mehta GU, Bradford D, Gittleman H, et al. FDA approval summary: belzutifan for von Hippel-Lindau disease-associated tumors. Clin Cancer Res. 2022;28(22):4843–8. https://doi.org/10.1158/1078-0432.Ccr-22-1054.CrossRefPubMedPubMedCentral

49.

Jonasch E, Donskov F, Iliopoulos O, Rathmell WK, Narayan VK, Maughan BL, et al. Belzutifan for renal cell carcinoma in von Hippel-Lindau disease. N Engl J Med. 2021;385(22):2036–46. https://doi.org/10.1056/NEJMoa2103425.CrossRefPubMedPubMedCentral

50.

Kamihara J, Hamilton KV, Pollard JA, Clinton CM, Madden JA, Lin J, et al. Belzutifan, a potent HIF2α inhibitor, in the Pacak-Zhuang syndrome. N Engl J Med. 2021;385(22):2059–65. https://doi.org/10.1056/NEJMoa2110051.CrossRefPubMed

Titel: Congenital Cyanotic Heart Disease and the Association with Pheochromocytomas and Paragangliomas
verfasst von: Robert Benson Jones Jr.
Debbie L. Cohen
Publikationsdatum: 17.10.2023
Verlag: Springer US
Erschienen in: Current Cardiology Reports / Ausgabe 11/2023
Print ISSN: 1523-3782
Elektronische ISSN: 1534-3170
DOI: https://doi.org/10.1007/s11886-023-01974-8

Neu im Fachgebiet Kardiologie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

24.05.2024 Diabetische Retinopathie Nachrichten

Möglicherweise hängt es von der Art der Diabetesmedikamente ab, wie hoch das Risiko der Betroffenen ist, dass sich sehkraftgefährdende Komplikationen verschlimmern.

TAVI versus Klappenchirurgie: Neue Vergleichsstudie sorgt für Erstaunen

21.05.2024 TAVI Nachrichten

Bei schwerer Aortenstenose und obstruktiver KHK empfehlen die Leitlinien derzeit eine chirurgische Kombi-Behandlung aus Klappenersatz plus Bypass-OP. Diese Empfehlung wird allerdings jetzt durch eine aktuelle Studie infrage gestellt – mit überraschender Deutlichkeit.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Congenital Cyanotic Heart Disease and the Association with Pheochromocytomas and Paragangliomas

Abstract

Purpose of Review

Recent Findings

Summary

Neu im Fachgebiet Kardiologie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

TAVI versus Klappenchirurgie: Neue Vergleichsstudie sorgt für Erstaunen

Update Kardiologie

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 11/2023

Using Patient Decision Aids for Cardiology Care in Diverse Populations

Tailored to a Woman’s Heart: Gender Cardio-Oncology Across the Lifespan

Coronary Angiography Complicated by Acute Ischaemic Stroke and the Use of Thrombolysis: a Cardiology Perspective and Narrative Review of Current Literature

Body Fat Distribution, Diabetes Mellitus, and Cardiovascular Disease: an Update

Advances in Screening for Radiation-Associated Cardiotoxicity in Cancer Patients

Preventative Imaging with Coronary Computed Tomography Angiography

Neu im Fachgebiet Kardiologie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

TAVI versus Klappenchirurgie: Neue Vergleichsstudie sorgt für Erstaunen

Update Kardiologie